Drug Profile
Research programme: mitochondrial function stimulants - MitoChem Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator MitoChem Therapeutics
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Retinal disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Retinal-disorders in USA (Ophthalmic, Drops)
- 02 Mar 2012 Preclinical trials in Retinal disorders in USA (Ophthalmic)
- 31 Dec 2009 Early research in Retinal disorders in USA (Ophthalmic)